Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:33.680Z.
Calculation as of: 2026-10-06T13:30:33.680Z.
Quote observation: 2026-10-06T13:30:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9de0dbfadb283a207fe687abae4d6c7414f83280ed3d33a9edf26fe3e5e7dd3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-01-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$819.44M
EV/EBIT Ratio
N/A
TTM Avg
103.45x
3Y Avg
72.64x
5Y Avg
72.64x
Market Cap
$867.60M
EV/EBIT Ratio
N/A
TTM Avg
76.83x
3Y Avg
76.83x
5Y Avg
76.83x
Market Cap
$786.48M
EV/EBIT Ratio
N/A
TTM Avg
501.20x
3Y Avg
422.57x
5Y Avg
422.57x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $837.43M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $850.45M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $850.75M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | N/A | 103.45x | 72.64x | 72.64x |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $812.20M | 6.08x | 7.17x | 8.31x | 13.83x |
| Apnimed, Inc. (APMD)vs › | $873.72M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 76.83x | 76.83x | 76.83x |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 501.20x | 422.57x | 422.57x |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | N/A | 13.71x | 14.97x | 19.98x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2015-01-30 | 10.37x |
| 2015-01-29 | 11.41x |
| 2015-01-28 | 11.64x |
| 2015-01-27 | 6.89x |
| 2015-01-26 | 7.93x |
| 2015-01-23 | 9.32x |
| 2015-01-22 | 8.40x |
| 2015-01-21 | 4.57x |
| 2015-01-20 | 5.73x |
| 2015-01-16 | 6.19x |
| 2015-01-15 | 2.48x |
| 2015-01-14 | 2.60x |
| 2015-01-13 | 1.09x |
| 2015-01-12 | 0.97x |
| 2015-01-09 | 0.28x |
| 2015-01-08 | 0.39x |
| 2014-12-22 | 1.44x |
| 2014-12-19 | 1.32x |
| 2014-12-18 | 1.79x |
| 2014-12-17 | 0.05x |
| 2014-12-12 | 20.11x |
| 2014-12-11 | 14.66x |
| 2014-12-10 | 15.47x |
| 2014-12-09 | 19.53x |
| 2014-12-08 | 21.61x |
| 2014-12-05 | 27.30x |
| 2014-12-04 | 27.06x |
| 2014-12-03 | 27.41x |
| 2014-12-02 | 16.74x |
| 2014-12-01 | 12.69x |
| 2014-11-28 | 9.67x |
| 2014-11-26 | 8.28x |
| 2014-11-25 | 1.44x |
| 2014-11-24 | 1.21x |
